BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant

ANAHEIM, CA, April 30, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today reported that Dr. Mark Siegel, commented on the advantages of sustained release naltrexone implants in treating addiction on Varney & Co. on Fox Business. The interview follows a similar report on Fox Business with actor Jeremy Miller, best known for his role as Ben Seaver on the hit TV show Growing Pains, in which Mr. Miller discussed how BioCorRx’s sustained release naltrexone has changed his life.

In the interview, Dr. Siegel commented on excitement around the concept of an implant that gradually releases the treatment. He further noted that the future of treating addiction will include products such as a sustained release naltrexone implant, which goes right to the source of the problem – addiction centers in the brain. As previously reported, BioCorRx is pursuing FDA marketing clearance for its sustained release naltrexone implant, BICX102.

The segment can be viewed online at

Dr. Marc Siegel, a practicing internist, joined FOX News Channel (FNC) as a contributor in 2008. In addition to his role at FNC, Dr. Siegel serves as an associate professor of medicine at NYU Langone Medical Center and as the Medical Director of Doctor Radio with NYU Langone and SiriusXM Satellite Radio.

Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM - 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.


Contact Data